Trials / Completed
CompletedNCT01065025
Open Label, Dose Escalation Trial of Oral Eg5 Kinesin-spindle Inhibitor 4SC-205 in Patients With Advanced Malignancies
Open Label, Dose Escalation Trial of Oral 4SC-205 in Patients With Advanced Malignancies: First-In-Man Study of a Newly Developed, Oral Inhibitor of Kinesin-spindle Protein, Eg5
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- 4SC AG · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to investigate safety and tolerability of repeated ascending oral doses of 4SC-205 in patients with advanced and incurable solid tumors or malignant lymphomas.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 4SC-205 | Repeated ascending oral doses of 4SC-205. |
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2015-04-01
- Completion
- 2015-04-01
- First posted
- 2010-02-09
- Last updated
- 2015-04-13
Locations
2 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT01065025. Inclusion in this directory is not an endorsement.